Novel Omeprazole Delayed Release Orally Disintegrating Tablets for Enhanced Patient Compliance: A Case of Model Informed Formulation Development

References

• Ahmed T, Kollipara S, Boddu R, Bhattiprolu A. K. (2023). Biopharmaceutics Risk Assessment-Connecting Critical Bioavailability Attributes with In Vitro, In Vivo Properties and Physiologically Based Biopharmaceutics Modeling to Enable Generic Regulatory Submissions. AAPS J. 25(5):77. doi: 10.1208/s12248-023-00837-y.
   Google Scholar
• Bhattiprolu A. K, Kollipara S, Ahmed T, Boddu R, Chachad S, (2022). Utility of Physiologically Based Biopharmaceutics Modeling (PBBM) in Regulatory Perspective: Application to Supersede f2, Enabling Biowaivers & Creation of Dissolution Safe Space. J. Pharm. Sci. 111(12):3397-3410. doi: 10.1016/j.xphs.2022.09.003.
   Google Scholar
• Boddu R, Kollipara S, Bhattiprolu A K, Ahmed T. (2023). Novel application of PBBM to justify impact of faster dissolution on safety and pharmacokinetics - a case study and utility in regulatory justifications. Xenobiotica, 53(10-11):587-602. doi: 10.1080/00498254.2023.2289160.
   Google Scholar
• Boddu R, Kollipara S, Vijaywargi G, Ahmed T. (2023). Power of integrating PBPK with PBBM (PBPK-BM): a single model predicting food effect, gender impact, drug-drug interactions and bioequivalence in fasting & fed conditions. Xenobiotica. 53(4):260-278. doi: 10.1080/00498254.2023.2238048.
   Google Scholar
• Boddu R, Kollipara S, Rachapally A, Ahmed T. (2024). Experience on Utilization of Novel Modeling & Simulation Approaches in Generic Product Development. J Biomed Res Environ Sci. 5(6): 588-596. doi: 10.37871/jbres1931.
   Google Scholar
• Declaration of Helsinki. (2008). Ethical principles for medical research involving human subjects. Adopted by the 18th WMA general assembly, Helsinki, Finland, June 1964, and amended by the WMA General Assembly, Seoul, Korea. [Accessed 27-06-2024]. https://www.wma.net/wp-content/uploads/2016/11/DoH-Oct2008.pdf
   Google Scholar
• Drug bank, [Accessed 27-06-2024], https://go.drugbank.com/salts/DBSALT000131
   Google Scholar
• EMA Guidance, (2016). Guideline on the reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation. [Accessed 27-06-2024] https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-reporting-physiologically-based-pharmacokinetic-pbpk-modelling-and-simulation_en.pdf
   Google Scholar
• GCP, Good Clinical Practices for Clinical Research in India. (2013). Central drugs standard control organization. Ministry of Health and Family Welfare, Government of India. [Accessed 27-06-2024]https://rgcb.res.in/documents/Good-Clinical-Practice-Guideline.pdf
   Google Scholar
• ICMR. (2017). National ethical guidelines for biomedical and health research involving human participants. Indian Council of Medical Research. [Accessed 27-06-2024] https://ethics.ncdirindia.org//asset/pdf/ICMR_National_Ethical_Guidelines.pdf
   Google Scholar
• Jaiswal S, Ahmed T, Kollipara S, Bhargava M, Chachad S. (2021). Development, validation and application of physiologically based biopharmaceutics model to justify the change in dissolution specifications for DRL ABC extended release tablets. Drug Dev Ind Pharm. 47(5):778-789. doi: 10.1080/03639045.2021.1934870.
   Google Scholar
• Kollipara S, Bhattiprolu A K, Boddu R, Ahmed T, Chachad S. (2023). Best Practices for Integration of Dissolution Data into Physiologically Based Biopharmaceutics Models (PBBM): A Biopharmaceutics Modeling Scientist Perspective. AAPS PharmSciTech.;24(2):59. doi: 10.1208/s12249-023-02521-y.
   Google Scholar
• Kollipara S, Martins F.S, Sanghavi M, Santos GML, Saini A, Ahmed T. (2024). Role of Physiologically Based Biopharmaceutics Modeling (PBBM) in Fed Bioequivalence Study Waivers: Regulatory Outlook, Case Studies and Future Perspectives, Journal of Pharmaceutical Sciences.113(2):345-358. doi: 10.1016/j.xphs.2023.11.030.
   Google Scholar
• Kollipara S, Bhattiprolu A. K, Boddu R, Ahmed T, Chachad S. (2023). Best Practices for Integration of Dissolution Data into Physiologically Based Biopharmaceutics Models (PBBM): A Biopharmaceutics Modeling Scientist Perspective. AAPS PharmSciTech, 24(2):59. doi: 10.1208/s12249-023-02521-y.
   Google Scholar
• Le Merdy M, AlQaraghuli F, Tan ML, Walenga R, Babiskin A, Zhao L, Lukacova V. (2023). Clinical Ocular Exposure Extrapolation for Ophthalmic Solutions Using PBPK Modeling and Simulation. Pharm Res. 40(2):431-447. doi: 10.1007/s11095-022-03390-z.
   Google Scholar
• Liu F, Merchant HA, Kulkarni RP, Alkademi M, Basit AW. (2011). Evolution of a physiological pH 6.8 bicarbonate buffer system: application to the dissolution testing of enteric coated products. Eur J Pharm Biopharm. 78(1):151-7. doi: 10.1016/j.ejpb.2011.01.001.
   Google Scholar
• Locatelli, I., Mrhar, A. & Bogataj, M. (2009). Gastric Emptying of Pellets under Fasting Conditions: A Mathematical Model. Pharm Res. 26:1607–1617. doi: 10.1007/s11095-009-9869-3.
   Google Scholar
• Mackie C, Arora S, Seo P, Moody R, Rege B, Pepin X, Heimbach T, Tannergren C, Mitra A, Suarez-Sharp S, Borges LN, Kijima S, Kotzagiorgis E, Malamatari M, Veerasingham S, Polli JE, Rullo G. (2024). Physiologically Based Biopharmaceutics Modeling (PBBM): Best Practices for Drug Product Quality, Regulatory and Industry Perspectives: 2023 Workshop Summary Report. Mol Pharm. 21(5):2065-2080. doi: 10.1021/acs.molpharmaceut.4c00202.
   Google Scholar
• Mondal S, Kollipara S, Chougule M, Bhatia A, Ahmed T. (2024). Biopredictive Dissolutions for Conventional Oral IR, MR and Non-Oral Formulations – Current Status and Future Opportunities. J Drug Del Sci Technol. 97:105807. doi: 10.1016/j.jddst.2024.105807.
   Google Scholar
• Ochoa D, Román M, Cabaleiro T, Saiz-Rodríguez M, Mejía G, Abad-Santos F. (2020). Effect of food on the pharmacokinetics of omeprazole, pantoprazole and rabeprazole. BMC Pharmacol Toxicol. 21(1):54. doi: 10.1186/s40360-020-00433-2.
   Google Scholar
• Oosterhuis B, Jonkman JH, Andersson T, Zuiderwijk PB. (1992). No influence of single intravenous doses of omeprazole on theophylline elimination kinetics. J Clin Pharmacol. 32(5):470-5. doi: 10.1002/j.1552-4604.1992.tb03864.x.
   Google Scholar
• Siemons M, Schroyen B, Darville N, Goyal N. (2023). Role of Modeling and Simulation in Preclinical and Clinical Long-Acting Injectable Drug Development. AAPS J. 25(6):99. doi: 10.1208/s12248-023-00864-9.
   Google Scholar
• Štefanič M, Locatelli I, Vrečer F, Sever T, Mrhar A, Bogataj M. (2012). The influence of gastric emptying kinetics on the drug release from enteric coated pellets in fasted state: An in vitro/in vivo correlation. Eur J Pharm Biopharm. 82(2): 376-382. doi: 10.1016/j.ejpb.2012.07.011.
   Google Scholar
• Tang C, Ou-Yang CX, Chen WJ, Zou C, Huang J, Cui C, Yang S, Guo C, Yang XY, Lin Y, Pei Q, Yang GP. (2022). Prediction of pharmacokinetic parameters of inhaled indacaterol formulation in healthy volunteers using physiologically-based pharmacokinetic (PBPK) model. Eur J Pharm Sci. 168:106055. doi: 10.1016/j.ejps.2021.106055.
   Google Scholar
• Tsakalozou, E., Fang, L., Bi, Y. et al. (2024). Experience Learned and Perspectives on Using Model-Integrated Evidence in the Regulatory Context for Generic Drug Products—a Meeting Report. AAPS J 26(14). doi: 10.1208/s12248-023-00884-5.
   Google Scholar
• USFDA Guidance. (2020). The Use of Physiologically Based Pharmacokinetic Analyses — Biopharmaceutics Applications for Oral Drug Product Development, Manufacturing Changes, and Controls. [Accessed 27-06-2024]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-physiologically-based-pharmacokinetic-analyses-biopharmaceutics-applications-oral-drug-product
   Google Scholar
• USFDA (2023). General Principles Model-integrated evidence (MIE) Industry Meeting Pilot between FDA and Generic drug applicants. [Accessed 27-06-2024]. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/model-integrated-evidence-mie-industry-meeting-pilot-between-fda-and-generic-drug-applicants
   Google Scholar
• USFDA label. (2017) [Accessed 27-06-2024]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209400Orig1s000lbl.pdf
   Google Scholar
• USFDA approved drugs database for omeprazole. [Accessed 27-06-2024]. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process
   Google Scholar
• USFDA SBOA data for omeprazole delayed release orally disintegrating Tablets (2016). [Accessed 27-06-2024]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209400Orig1s000ClinPharmR.pdf
   Google Scholar
• USFDA Prilosec Label. (2016). [Accessed 27-06-2024]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019810s102,022056s019lbl.pdf
   Google Scholar
• USFDA Prilosec SBOA. (2003). [Accessed 27-06-2024]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-229_Prilosec_biopharmr.pdf
   Google Scholar
• USFDA workshop. (2023) [Accessed 27-06-2024]. https://www.fda.gov/news-events/advances-pbpk-modeling-and-its-regulatory-utility-oral-drug-product-development-10122023
   Google Scholar
• USFDA workshop. (2024) [Accessed 27-06-2024]. https://www.fda.gov/drugs/news-events-human-drugs/fdacrcg-workshop-considerations-and-potential-regulatory-applications-model-master-file-05022024
   Google Scholar
• Wu F, Mousa Y, Jereb R. et al. (2024). Using Mechanistic Modeling Approaches to Support Bioequivalence Assessments for Oral Products. AAPS J. 26(19). doi: 10.1208/s12248-024-00886-x.
   Google Scholar